SCHEMBL6403626

SCHEMBL6403626

CC(CCc1ccc(O)cc1SP(=O)(O)O)c1cccc(O)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 2/20 0.37
ADRB1 P08588 2/20 0.35
ADRA1A P35348 2/20 0.35
MIF P14174 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2B P41595 1/20 0.35
HIF1A Q16665 4/20 0.33
DRD3 P35462 2/20 0.33
ADRB2 P07550 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRB3 P13945 1/20 0.33
TSHR P16473 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
NFKB1 P19838 1/20 0.33
DRD1 P21728 1/20 0.33
HTR7 P34969 1/20 0.33
ADRA1B P35368 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6394482 0.91 ADRB1 (0.35) TYRADRB1ADRA1AMIFHTR2A
SCHEMBL6396741 0.89 TYR (0.39) TYRMIF
SCHEMBL6396463 0.88 ADRB1 (0.36) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL6401210 0.83 HDAC4 (0.34) TYRADRB1ADRA1AMIFHTR2A
SCHEMBL6395611 0.82 HDAC4 (0.37) TYRADRB1ADRA1AMIFHTR2A
SCHEMBL6397878 0.81 ESR1 (0.36) TYRMIF
SCHEMBL6403628 0.81 TYR (0.39) TYRADRB1ADRA1AMIFHTR2A
SCHEMBL6403713 0.80 ADRB1 (0.36) ADRB1ADRA1AMIFHTR2AHTR2B
SCHEMBL6394487 0.79 ADRB1 (0.37) TYRADRB1ADRA1AMIFHTR2A
SCHEMBL6404162 0.78 HTR2A (0.42) TYRADRB1ADRA1AMIFHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 TYR 3689/4885ADRB1 1543/4885ADRA1A 2552/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 TYR 3556/4885ADRB1 1645/4885ADRA1A 2707/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 TYR 3689/4885ADRB1 1543/4885ADRA1A 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.